GSK China's Strategic Restructuring to Regain Market Position

In recent news, it has been reported by industry media that GSK China is set to undergo a major restructuring starting from January 1, 2024. The restructuring will involve the formation of three core business divisions: Specialty Medicines, Vaccines, and Respiratory. This move aims to realign and reorganize GSK's existing business sectors, including General Medicines, Core Prescription Medicines, and HIV. According to the reports, the head of the Vaccine Business Division, Bi-Xia Feng, will remain unchanged, while the leader of the Respiratory Business Division (General Medicines, IL-5), Jin-Yi Yu, will transition to the head of the Specialty Medicines Business Division. The vacant position in the Specialty Medicines Business Division (SLE, HEP, HIV) will be filled by Xin Qi, who will serve as the interim leader until a new appointment is announced.

Background:
Looking back at the beginning of the year, on January 3, Xu Ding stepped down as Vice President of GSK China and the head of the Respiratory Business Division. On January 4, Jin-Yi Yu, the former Chief Business Officer of Sanofi Pasteur China, joined GSK China and assumed the roles of Vice President and head of the Respiratory Business Division. On September 8, Jin-Yi Yu was appointed as Vice President and head of the Specialty Medicines Business Division. After Jin-Yi Yu officially took office as the head of the Specialty Medicines Business Division, on November 20, the sales team of Benlysta (belimumab) underwent reorganization, with five regions established to accelerate the sales growth of core products in the specialty medicines field.

Furthermore, it is worth mentioning that GSK China's move aligns with the restructuring of its research and development (R&D) department, which was announced on September 18. Following the departure of John Lepore, the former Senior Vice President and Head of R&D, the R&D department underwent adjustments and was divided into three teams: Respiratory and Immunology, Vaccines and Infectious Diseases, and Oncology.

Market Challenges and Vision:
Throughout this year's series of adjustments, GSK's actions have been closely linked to its declining ranking in the Chinese market. With the disclosure of the third-quarter financial report, Merck surpassed AstraZeneca to claim the top spot in the Chinese market with its cancer drug Keytruda and the 9-valent HPV vaccine. Although GSK's Q3 financial report showed a revenue of £8.147 billion, a 10% year-on-year increase, it fell somewhat short compared to other multinational pharmaceutical companies vying for the Chinese market. GSK China announced its vision for 2030, aiming to be among the top ten multinational pharmaceutical companies in China. To achieve this goal, restructuring the team is one aspect, but GSK also needs to enhance its own capabilities.

Business Overview:
When it comes to GSK's specific business sectors in China, the heavyweight products in the specialty medicines sector cannot be overlooked, with Benlysta playing a crucial role. Benlysta was first approved in China in 2019, and on December 13 of this year, it successfully renewed its inclusion in the 2023 National Reimbursement Drug List and added an indication for adult lupus nephritis (LN). It is worth noting that Benlysta is the world's first biologic therapy to cover both adult and pediatric systemic lupus erythematosus (SLE) and adult lupus nephritis indications. It is the only biologic therapy recommended by the Chinese guidelines, the European League Against Rheumatism (EULAR) guidelines, and the Kidney Disease Improving Global Outcomes (KDIGO) guidelines for the treatment of systemic lupus erythematosus. Benlysta is indispensable for achieving GSK's vision of being among the top ten pharmaceutical companies in China. Additionally, GSK's Ellipta (umeclidinium/vilanterol inhalation powder) and Dovato (dolutegravir/lamivudine tablets) have also achieved successful renewals, serving as treatments for chronic obstructive pulmonary disease and human immunodeficiency virus (HIV) infection, respectively.

Significant Developments in the Vaccine Sector:
The vaccine sector has also seen significant developments this year. On October 8, GSK announced the restructuring of its herpes zoster vaccine Shingrix, appointing Chongqing Zhifei Biological Products as its distributor and setting a minimum purchase amount of 20.64 billion yuan for the next three years. According to Frost Sullivan's estimates, the Chinese market for herpes zoster vaccines is projected to reach 28.1 billion yuan by 2030 based on sales revenue.

In addition to Shingrix, GSK introduced another breakthrough vaccine in May this year, Arexvy, the world's first approved recombinant respiratory syncytial virus (vaccine for infants. Arexvy received approval from the National Medical Products Administration (NMPA) in China and has the potential to address a significant unmet medical need in protecting infants from respiratory syncytial virus (RSV) infections. This vaccine represents an important addition to GSK's vaccine portfolio in China and can contribute to its growth and market position.

GSK China's strategic restructuring, set to take effect from January 1, 2024, aims to realign and reorganize its business divisions to regain its market position. By establishing three core business divisions focused on Specialty Medicines, Vaccines, and Respiratory, GSK aims to optimize its operations and enhance its capabilities in these key therapeutic areas. With a vision to be among the top ten multinational pharmaceutical companies in China by 2030, GSK's restructuring is a step toward achieving this goal. The company's focus on specialty medicines such as Benlysta, along with significant developments in the vaccine sector, demonstrates its commitment to addressing unmet medical needs and capturing opportunities in the Chinese market.